THERAVANCE BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.12 USD | -0.22% |
|
-2.36% | -18.86% |
| Apr. 12 | Sector Update: Health Care Stocks Lower Friday Afternoon | MT |
| Apr. 12 | Theravance Biopharma Shares Rise After BTIG Starts Coverage at Buy | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,470 | 1,137 | 814.4 | 754.5 | 559.7 | 442.9 | - | - |
| Enterprise Value (EV) 1 | 1,652 | 1,463 | 1,310 | 479.2 | 559.7 | 442.9 | 442.9 | 442.9 |
| P/E ratio | -6.09 x | -3.98 x | -3.85 x | 0.95 x | -11.2 x | -13.5 x | -22.8 x | 12.2 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 20 x | 15.8 x | 14.7 x | 14.7 x | 9.75 x | 6.27 x | 4.79 x | 3.21 x |
| EV / Revenue | 20 x | 15.8 x | 14.7 x | 14.7 x | 9.75 x | 6.27 x | 4.79 x | 3.21 x |
| EV / EBITDA | -5,903,691 x | -3,938,247 x | -4,290,640 x | -15,555,365 x | - | - | - | - |
| EV / FCF | -6.09 x | -4.42 x | -3.85 x | - | - | -34.1 x | 63.3 x | 4.03 x |
| FCF Yield | -16.4% | -22.6% | -25.9% | - | - | -2.94% | 1.58% | 24.8% |
| Price to Book | - | -3.76 x | -2.43 x | 1.66 x | - | - | - | - |
| Nbr of stocks (in thousands) | 56,762 | 63,981 | 73,698 | 67,250 | 49,798 | 48,560 | - | - |
| Reference price 2 | 25.89 | 17.77 | 11.05 | 11.22 | 11.24 | 9.120 | 9.120 | 9.120 |
| Announcement Date | 2/24/20 | 2/23/21 | 2/23/22 | 2/27/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 73.41 | 71.86 | 55.31 | 51.35 | 57.42 | 70.68 | 92.36 | 138.1 |
| EBITDA | -248.9 | -288.7 | -189.8 | -48.51 | - | - | - | - |
| EBIT 1 | -251.9 | -297.8 | -257.8 | -91.96 | -56.04 | -29.45 | -33.96 | -17.77 |
| Operating Margin | -343.14% | -414.37% | -466.06% | -179.09% | -97.58% | -41.66% | -36.77% | -12.87% |
| Earnings before Tax (EBT) 1 | -241.7 | -286.5 | -199.6 | -92.82 | -49.27 | -23.94 | -33.55 | 44.95 |
| Net income 1 | -236.5 | -278 | -199.4 | 872.1 | -55.19 | -33 | -19.61 | 38.67 |
| Net margin | -322.08% | -386.9% | -360.55% | 1,698.54% | -96.11% | -46.69% | -21.23% | 28.01% |
| EPS 2 | -4.250 | -4.460 | -2.870 | 11.85 | -1.000 | -0.6750 | -0.4000 | 0.7475 |
| Free Cash Flow 1 | -241.4 | -257 | -211.3 | - | - | -13 | 7 | 110 |
| FCF margin | -328.78% | -357.68% | -381.96% | - | - | -18.39% | 7.58% | 79.68% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 284.43% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/24/20 | 2/23/21 | 2/23/22 | 2/27/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 13.19 | 14.94 | 13.2 | 11.05 | 12.45 | 14.65 | 10.42 | 13.75 | 15.69 | 17.56 | 13.95 | 16.06 | 17.08 | 23.57 | - |
| EBITDA | -51.99 | -37.89 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -53.62 | -56.17 | -38.5 | -26.88 | -14.2 | -17.43 | -24.91 | -16.12 | -8.76 | -6.241 | -10.4 | -9.752 | -8.797 | -0.462 | - |
| Operating Margin | -406.36% | -375.82% | -291.77% | -243.25% | -114.06% | -119% | -239.15% | -117.27% | -55.82% | -35.53% | -74.56% | -60.73% | -51.5% | -1.96% | - |
| Earnings before Tax (EBT) 1 | -35.32 | -32.19 | -25.42 | -8.196 | -16.02 | -14.26 | -22.48 | -14.19 | -7.583 | -5.017 | -8.943 | -9.47 | -8.741 | 3.21 | - |
| Net income 1 | -35.31 | -32.04 | -25.95 | -8.191 | 916.6 | -10.36 | -22.09 | -15.64 | -8.95 | -8.511 | -12.48 | -10.49 | -8.608 | -1.425 | -14.55 |
| Net margin | -267.61% | -214.35% | -196.62% | -74.13% | 7,361.91% | -70.75% | -212.04% | -113.79% | -57.03% | -48.45% | -89.44% | -65.32% | -50.39% | -6.05% | - |
| EPS 2 | -0.4800 | -0.4300 | -0.3400 | -0.1100 | 12.14 | -0.1500 | -0.3500 | -0.2800 | -0.1700 | -0.1700 | -0.2525 | -0.2125 | -0.1725 | -0.0325 | -0.3000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/3/21 | 2/23/22 | 5/5/22 | 8/8/22 | 11/7/22 | 2/27/23 | 5/8/23 | 8/7/23 | 11/7/23 | 2/26/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | 182 | 326 | 496 | - | - | - | - | - |
| Net Cash position | - | - | - | 275 | - | - | - | - |
| Leverage (Debt/EBITDA) | -0.731 x | -1.13 x | -2.614 x | - | - | - | - | - |
| Free Cash Flow 1 | -241 | -257 | -211 | - | - | -13 | 7 | 110 |
| ROE (net income / shareholders' equity) | - | - | - | -85.7% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | -63.3% | -47.3% | - | - | - | - | - |
| Assets 1 | - | 438.9 | 421.9 | - | - | - | - | - |
| Book Value Per Share | - | -4.720 | -4.550 | 6.770 | - | - | - | - |
| Cash Flow per Share | -4.280 | - | -2.990 | - | - | - | - | - |
| Capex | 3.18 | 6.62 | 3.41 | - | - | - | - | - |
| Capex / Sales | 4.33% | 9.21% | 6.16% | - | - | - | - | - |
| Announcement Date | 2/24/20 | 2/23/21 | 2/23/22 | 2/27/23 | 2/26/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
9.12
USD
Average target price
15.4
USD
Spread / Average Target
+68.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.86% | 443M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- TBPH Stock
- Financials Theravance Biopharma, Inc.
